Welcome to our dedicated page for OmniAb SEC filings (Ticker: OABIW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OmniAb's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OmniAb's regulatory disclosures and financial reporting.
Orchestra BioMed (OABI) insider Charles S. Berkman has filed a Rule 144 notice for planned stock sales. The filing covers intended sales of 6,891 and 9,541 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ around February 17 and 18, 2026, with stated aggregate market values of $11,714.70 and $16,219.70.
The shares to be sold were acquired as restricted stock compensation from the issuer, including 13,542 shares on February 16, 2026 and 18,750 shares on February 18, 2026. The notice also reports a prior sale on December 8, 2025 of 8,044 common shares for gross proceeds of $15,773.84. By signing, the seller represents that he is not aware of any undisclosed material adverse information about the company.
Orchestra BioMed (OABI) insider Charles S. Berkman has filed a Rule 144 notice for planned stock sales. The filing covers intended sales of 6,891 and 9,541 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ around February 17 and 18, 2026, with stated aggregate market values of $11,714.70 and $16,219.70.
The shares to be sold were acquired as restricted stock compensation from the issuer, including 13,542 shares on February 16, 2026 and 18,750 shares on February 18, 2026. The notice also reports a prior sale on December 8, 2025 of 8,044 common shares for gross proceeds of $15,773.84. By signing, the seller represents that he is not aware of any undisclosed material adverse information about the company.
OABI insider Kurt A. Gustafson filed a notice of proposed sales under Rule 144 for common stock. The filing lists planned sales of 6,891 and 9,173 shares of common stock through Morgan Stanley Smith Barney on NASDAQ on 02/17/2026 and 02/18/2026, with aggregate market values of $11,714.70 and $15,594.10. The issuer had 143,955,400 shares of common stock outstanding. The shares to be sold were acquired as restricted stock compensation, including 13,542 shares on 02/16/2026 and 18,750 shares on 02/18/2026. The filing also notes a prior sale of 23,922 common shares on 12/08/2025 for gross proceeds of $46,909.73.
OABI insider Kurt A. Gustafson filed a notice of proposed sales under Rule 144 for common stock. The filing lists planned sales of 6,891 and 9,173 shares of common stock through Morgan Stanley Smith Barney on NASDAQ on 02/17/2026 and 02/18/2026, with aggregate market values of $11,714.70 and $15,594.10. The issuer had 143,955,400 shares of common stock outstanding. The shares to be sold were acquired as restricted stock compensation, including 13,542 shares on 02/16/2026 and 18,750 shares on 02/18/2026. The filing also notes a prior sale of 23,922 common shares on 12/08/2025 for gross proceeds of $46,909.73.
OmniAb, Inc. received an updated Schedule 13G/A showing that several related investment entities and individuals collectively hold meaningful passive stakes in its common stock. As of December 31, 2025, Robert Goldstein may have been deemed to beneficially own approximately 8.5% of OmniAb’s common shares, or 12,291,972 shares, through direct holdings and control positions in various entities. Ash X LP and its general partner RLG GP LLC each may have been deemed to beneficially own 7,557,202 shares, or about 5.3% of the company. RLG Capco II LLC may have been deemed to beneficially own 4,733,575 shares, or about 3.3%. Joel Greenblatt may have been deemed to beneficially own 1,429,766 shares, or about 1.0%. All percentages are based on 143,955,400 shares outstanding as of October 28, 2025. The reporting group certifies the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of OmniAb.
OmniAb, Inc. received an updated Schedule 13G/A showing that several related investment entities and individuals collectively hold meaningful passive stakes in its common stock. As of December 31, 2025, Robert Goldstein may have been deemed to beneficially own approximately 8.5% of OmniAb’s common shares, or 12,291,972 shares, through direct holdings and control positions in various entities. Ash X LP and its general partner RLG GP LLC each may have been deemed to beneficially own 7,557,202 shares, or about 5.3% of the company. RLG Capco II LLC may have been deemed to beneficially own 4,733,575 shares, or about 3.3%. Joel Greenblatt may have been deemed to beneficially own 1,429,766 shares, or about 1.0%. All percentages are based on 143,955,400 shares outstanding as of October 28, 2025. The reporting group certifies the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of OmniAb.
OmniAb, Inc. director John L. Higgins reported the vesting of 13,172 restricted stock units (RSUs) and the corresponding acquisition of 13,172 shares of common stock on January 30, 2026.
The RSUs vest in three substantially equal annual installments beginning January 30, 2024, conditioned on his continued service. After this transaction, he beneficially owns 2,942,320 shares of common stock and 20,000 RSUs directly.
OmniAb, Inc. director John L. Higgins reported the vesting of 13,172 restricted stock units (RSUs) and the corresponding acquisition of 13,172 shares of common stock on January 30, 2026.
The RSUs vest in three substantially equal annual installments beginning January 30, 2024, conditioned on his continued service. After this transaction, he beneficially owns 2,942,320 shares of common stock and 20,000 RSUs directly.
OmniAb, Inc. reports that its Board of Directors approved and adopted amended and restated bylaws effective January 30, 2026. The updated bylaws address the SEC’s universal proxy rules by clarifying that no one may solicit proxies for director nominees other than the Board’s nominees unless they comply with Rule 14a-19, including its notice and solicitation requirements.
The bylaws also modernize and enhance procedures for stockholder director nominations and other business at stockholder meetings, requiring additional background information and disclosures about proposing stockholders, proposed nominees, related persons, and their ownership of OmniAb securities. The filing notes further technical, modernizing and clarifying changes, with full text provided in attached exhibits.
OmniAb, Inc. reports that its Board of Directors approved and adopted amended and restated bylaws effective January 30, 2026. The updated bylaws address the SEC’s universal proxy rules by clarifying that no one may solicit proxies for director nominees other than the Board’s nominees unless they comply with Rule 14a-19, including its notice and solicitation requirements.
The bylaws also modernize and enhance procedures for stockholder director nominations and other business at stockholder meetings, requiring additional background information and disclosures about proposing stockholders, proposed nominees, related persons, and their ownership of OmniAb securities. The filing notes further technical, modernizing and clarifying changes, with full text provided in attached exhibits.
Schedule 13G/A filed for OmniAb, Inc. (OABI) discloses that several related entities and individuals report beneficial ownership of the issuer's common stock. Ash X LP and RLG GP each report ownership of 8,271,347 shares, representing approximately 5.8% of the outstanding common stock. RLG Capco II LLC holds 1,800,246 shares (about 1.3%) and Joel Greenblatt holds 1,428,571 shares (about 1.0%). Robert Goldstein is reported as beneficial owner of 10,071,593 shares (about 7.0%), reflecting combined holdings through entities he controls. The percentages are calculated using 122,701,294 shares outstanding as of July 30, 2025 plus 21,254,106 additional shares issued on August 25, 2025. The filing states the holdings are not intended to influence control of the issuer.